The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of adjuvant mFOLFOX6 after metastasectomy for pulmonary metastasis of colorectal cancer: WJOG5810G.
 
Nozomu Machida
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca
Research Funding - MSD
 
Takehiro Okumura
No Relationships to Disclose
 
Junji Kishimoto
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Nihonkayaku; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Koichi Suyama
No Relationships to Disclose
 
Yasuhisa Ohde
No Relationships to Disclose
 
Katsunori Shinozaki
Honoraria - Asahi Kasei; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Merck; Mochida Pharmaceutical Co. Ltd.; Nihonkayaku; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Takeda
 
Hideo Baba
Honoraria - Lilly
Research Funding - Chugai Pharma (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Shin Nippon Biomedical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Shinya Tokunaga
No Relationships to Disclose
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Takashi Tsuda
No Relationships to Disclose
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Hiroyuki Okuda
No Relationships to Disclose
 
Hisateru Yasui
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Taiho Pharmaceutical; TERUMO; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Tadamichi Denda
Speakers' Bureau - Chugai Pharma (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
Research Funding - MSD (Inst)
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Shuichi Hironaka
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; MSD K.K; Ono Pharmaceutical
 
Kei Muro
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst)
 
Ichinosuke Hyodo
Honoraria - Asahi Kasei; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Asahi Kasei
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)